<DOC>
	<DOC>NCT00803907</DOC>
	<brief_summary>This study aimed to prove the efficacy and safety of the use of imiquimod 5% cream in the periorbital region.</brief_summary>
	<brief_title>Imiquimod 5% Cream for the Treatment of Periocular Basal Cell Carcinoma</brief_title>
	<detailed_description>This is a prospective study including patients presenting in aggregate primary lesions affected by nodular BCC of the eyelid (all subjects were submitted to incisional biopsy at 2 mm punch) at the commencement of this study. All were submitted to a local treatment with Imiquimod 5% cream (Aldara Â®), once daily, 5 days per week for 8-16 weeks (average). All subjects were submitted to a new incisional biopsy at 2 mm punch, after 12 weeks of treatment, and all of them were monitored monthly up to now.If positive biopsy (residue tumor) cases will managed with surgery.</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Basal Cell</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<mesh_term>Adjuvants, Immunologic</mesh_term>
	<mesh_term>Immunologic Factors</mesh_term>
	<criteria>Patients whose injuries were confirmed by anatomical and pathological study (periocular superficial basal cell carcinoma). Patients with clinical counter indication for reconstructive surgery (high surgical risk). Patients who have refused a restorative surgery. (aesthetic reasons) Patients who have signed the free and informed consent. Patients who have a hypersensitivity reaction to the formula components. Children under 12 years of age. Pregnant and breastfeeding women. Patients whose injury was not confirmed by anatomical and pathological study. Individuals with previous autoimmune or inflammatory disease. Patients who have refused to sign the free and informed term of consent.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>immunomodulator</keyword>
	<keyword>Carcinoma, Basal Cell</keyword>
</DOC>